Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A2 inhibitors, SPI
- 18 November 1999
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1441 (2-3) , 223-228
- https://doi.org/10.1016/s1388-1981(99)00157-2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- REGULATION AND INHIBITION OF PHOSPHOLIPASE A2Annual Review of Pharmacology and Toxicology, 1999
- Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitorsEuropean Journal of Pharmacology, 1996
- Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 3. Indole-3-glyoxamidesJournal of Medicinal Chemistry, 1996
- Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2Nature Structural & Molecular Biology, 1995
- Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluidsInflammation, 1992
- Structures of Free and Inhibited Human Secretory Phospholipase A 2 from Inflammatory ExudateScience, 1991
- Critical role of a hydrogen bond in the interaction of phospholipase A2 with transition-state and substrate analogues.Proceedings of the National Academy of Sciences, 1991
- Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritisInflammation, 1991
- Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 Å resolutionNature, 1991
- X-ray structure of phospholipase A2 complexed with a substrate-derived inhibitorNature, 1990